RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Impact of nanomedicine on hepatic cytochrome P450 3A4 activity: things to consider during pre-clinical and clinical studies

        Kristina Jonsson‑Schmunk,Stephen C. Schafer,Maria A. Croyle 한국약제학회 2018 Journal of Pharmaceutical Investigation Vol.48 No.1

        Hepatic cytochrome P450 3A4 (CYP3A4) is an important drug-metabolizing enzyme as it is responsible for metabolizing over 30% of currently marketed drugs across most therapeutic classes. CYP3A4 is regulated at various stages including transcriptional, post-transcriptional, translational and post-translational expression. Changes made at any of these stages of CYP3A4 regulation could result in fluctuations in CYP3A4 levels and/or activity. These alterations are important to understand as they could lead to drug–drug interactions, sub-therapeutic levels or toxic levels of pharmaceutical drugs. Nanomedicine, the use of nanotechnology for treatment, diagnosis and monitoring of biological systems, is a growing market. This includes use of viral vectors for gene transfer and vaccine applications and nanoparticles based on gold and silver for various applications. Both have shown to alter CYP3A4 activity and function. Hence, during pre-clinical and clinical studies it is important to elucidate any effect of nanomedicines on CYP3A4 to avoid unintended changes in maintenance of medications due to changes in drug metabolism.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼